What You Should Know: – Today, Blue Cross and Blue Shield of North Carolina partners with Carrot Inc. and Virta Health to help address two of the largest ongoing health issues facing Americans today – smoking and type 2 diabetes. – Virta and Carrot’s programs… Read More »Blue Cross NC Launches No-Cost Virtual Programs to Quit Smoking and Reverse Diabetes
Shots: The CHMP’s positive opinion is based on P-III ETHOS & KRONOS studies, which are a part of AstraZeneca’s P-III ATHENA program assessing Trixeo Aerosphere in 15500+ patients globally across 11 trials P-III ETHOS study results reported that triple-combination therapy showed a reduction in the… Read More »AstraZeneca’s Trixeo Aerosphere Receives CHMP’s Recommendation for Approval to Treat COPD
AireHealth, which makes portable nebulizers for patients with respiratory conditions, plans to launch its first connected product next year.
Verona Pharma is to develop its lung drug ensifentrine for patients with COVID-19, joining the legions of drug companies repurposing their medicines to fight the pandemic. Based in the UK and US, Verona is due to start a phase 3 trial of ensifentrine in chronic… Read More »Verona Pharma to trial lung drug ensifentrine for COVID-19
What You Should Know: – Innovaccer has recently partnered with CareSignal to address healthcare’s urgent need amidst the COVID-19 pandemic: to create and maintain solid, clinically actionable relationships with patients in a new set of predominantly virtual care. – CareSignal offers evidence-based end-to-end support services… Read More »Innovaccer, CareSignal Partner to Enable Deviceless Remote Patient Monitoring
Shots: The approval is based on P-III ETHOS study assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] with mod. to sev. COPD and a history of exacerbation(s) in the previous year The P-III ETHOS study demonstrated… Read More »AstraZeneca’s Breztri Aerosphere Receives the US FDA’s Approval for the Maintenance Treatment of COPD
AstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the US following a rejection last year. Approval follows a rejection by the FDA in October last year after the FDA refused to grant a licence based on… Read More »AZ’s COPD triple therapy approved in the US
Teva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to a phone to help manage asthma and COPD symptoms. Israel-based Teva said the system conveys information to patients, who can use the product branded as ProAir Digihaler (albuterol sulfate) for patients… Read More »Teva launches digital asthma and COPD rescue inhaler in US
What You Should Know: – Propeller Health announced it will co-package a new asthma medication from Novartis, which was approved by the European Commission this week for use in the EU. – Enerzair® Breezhaler® plus Propeller Health sensor is the first asthma medication to be… Read More »Propeller Health, Novartis Co-Package Asthma Medication in Europe for Prescription
<div class="right-align"> <a class="btn btn-blue _gt" data-category="Hospital" data-action="Click-Button" data-label="Blog-Reducing Respiratory Failure Readmissions While COPD Is on the Rise" href="https://www.kindredhealthcare.com/docs/default-source/default-document-library/kindred-respiratory-failure-whitepaper.pdf?sfvrsn=74f58dea_2" title="Reducing Respiratory Failure Readmissions While COPD Is on the Rise" target="_blank">Download this article as a PDF</a></div> <br /> <p>Diagnoses of Chronic Obstructive Pulmonary Disease (COPD) have… Read More »Reducing Respiratory Failure Readmissions While COPD Is on the Rise
